Pelthos Therapeutics Inc.
$22.95
▼
-4.23%
2026-04-21 08:59:01
pelthos.com
ASE: PTHS
Explore Pelthos Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$77.23 M
Current Price
$22.95
52W High / Low
$54.29 / $9
Stock P/E
—
Book Value
$12.02
Dividend Yield
—
ROCE
-31.06%
ROE
-2.4%
Face Value
—
EPS
$-23.04
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
92
Beta
3.99
Debt / Equity
89.58
Current Ratio
2.06
Quick Ratio
1.15
Forward P/E
-215.05
Price / Sales
4.51
Enterprise Value
$92.62 M
EV / EBITDA
-3.18
EV / Revenue
5.51
Rating
Strong Buy
Target Price
$57.14
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Evogene Ltd. | $0.8 | — | $7.92 M | — | -84.53% | -1.01% | $2.42 / $0.72 | $-0.01 |
| 2. | BioVie Inc. | $1.58 | — | $11.77 M | — | -93.67% | -80.74% | $13.2 / $1.06 | $2.56 |
| 3. | Virax Biolabs Group Limited | $0.14 | — | $1.05 M | — | -107.11% | -83.82% | $1.2 / $0.1 | $0.81 |
| 4. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
| 5. | Eledon Pharmaceuticals, Inc. | $4.14 | — | $314.03 M | — | -55.26% | -35.79% | $4.6 / $1.35 | $1.81 |
| 6. | Zymeworks Inc. | $27.85 | — | $1.98 B | — | -30.42% | -26.72% | $28.49 / $10.86 | $3.6 |
| 7. | Jade Biosciences, Inc. | $23.5 | — | $1.13 B | 0% | -34.07% | -89.19% | $100.1 / $6.57 | $6.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 9.39 M | 7.41 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -12 M | -15.36 M | -3.23 M | -1.83 M | -1.83 M | — |
| Net Profit | -21.66 M | -16.24 M | -3.45 M | -1.97 M | -1.93 M | — |
| EPS in Rs | -6.46 | -4.84 | -1.03 | -0.59 | -0.57 | -2.93 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 16.8 M | 0 M | 0 M | 0 M |
| Operating Profit | -32.43 M | -7.57 M | -6.86 M | -2.32 M |
| Net Profit | -43.32 M | -7.96 M | -7.38 M | -2.46 M |
| EPS in Rs | -12.91 | -2.37 | -2.2 | -0.73 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 130.4 M | 1.37 M | 0.1 M | 0.06 M |
| Total Liabilities | 91.52 M | 4.08 M | 6.54 M | 3.76 M |
| Equity | 38.88 M | -2.71 M | -6.44 M | -3.71 M |
| Current Assets | 53.41 M | 1.37 M | 0.1 M | 0.06 M |
| Current Liabilities | 25.99 M | 4.08 M | 6.54 M | 3.76 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -22.59 M | -5.79 M | -0.98 M | -1.57 M |
| Investing CF | -5.24 M | 0 M | — | — |
| Financing CF | 45.34 M | 6.21 M | 1.02 M | 1.62 M |
| Free CF | -30.59 M | -5.79 M | -0.98 M | -1.57 M |
| Capex | -8 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -7.78% | -200.2% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-02 | 1:0.1 |